Platelet Activating Factor Causes Relaxation of Isolated Pulmonary Artery and Aorta

  • Najia Jin
  • C. Subah Packer
  • Rodney A. Rhoades
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 304)


Platelet activating factor (PAF) is a lipid chemical mediator produced by a variety of activated cells, including basophils, eosinophils, platelets, monocytes, endothelial cells, macrophages, and neutrophils (Tamura, 1987; Vercellotti, 1988). A number of pathophysiological responses, such as inflammatory and allergic reactions, bronchoconstriction, platelet aggregation, pulmonary hypertension, anaphylactic shock, endotoxic shock, and systemic hypotension are mediated by PAF (Benveniste and Vargaftig, 1983; Heffner, 1983a; 1983b; Terashita, 1985; 1987; Hanahan, 1986; Barnes, 1988). These pathological conditions are linked to changes in smooth muscle tone. For example, bronchoconstriction is due to the increase in tone of airway smooth muscle and hypotension is due to the decrease in tone of vascular smooth muscle.


Pulmonary Hypertension Platelet Activate Factor Airway Smooth Muscle Aortic Ring Anaphylactic Shock 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Barnes, D. J., Chung, K. F., and Page, C. P., 1988, Platelet-activating factor as a mediator of allergic disease, J. Allerg. Clin. Immunol., 81: 919.CrossRefGoogle Scholar
  2. Benveniste, J. and Vargaftig, B. B., 1983, Platelet-activating factor: An ether lipid with biological activity, in: “Ether Lipids-Biochemical and Biomedical Aspects”, H. K. Mangold, F. Paltauf, eds., Academic Press, New York, p. 355.Google Scholar
  3. Chen, C. R., Voelkel, N. F., and Chang, S. W., 1990, PAF potentiates protamine-induced lung edema: Role of pulmonary venoconstriction, J. Appl. Physiol., 68: 1059.PubMedCrossRefGoogle Scholar
  4. Feuerstein, G., Lux, W. E., Snyder, F., Ezra, D., and Faden, A. I., 1984, Hypotension produced by platelet-activating factor is reversed by thyrotropine-releasing hormone, Circ. Shock, 13: 255.PubMedGoogle Scholar
  5. Goldstein, B. M., Gabel, R. A., Huggins, F. J., Cervoni, P., and Crandall, D.J., 1984, Effect of platelet-activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat, Life Sci., 35: 1373.PubMedCrossRefGoogle Scholar
  6. Hamasaki, Y., Mojarad, M., Saga, T., Tai, H. H., and Said, S. I., 1984, Platelet-activating factor raises airway and vascular pressure and induces edema in lungs perfused with platelet free solution, Am. Rev. Resp. Dis., 129: 742.PubMedGoogle Scholar
  7. Hanahan, D. J., 1986, Platelet activating factor: A biologically active phosphoglyceride, Ann. Rev. Biochem., 55: 483.PubMedCrossRefGoogle Scholar
  8. Heffner, J. E., Shoemaker, S. A., Canham E. M., Patel, M., McMurtry, I. F., Morris, H. G., and Repine, J. E., 1983a, Platelet-induced pulmonary hypertension and edema, Chest, 83: 78s.Google Scholar
  9. Heffner, J. E., Shoemaker, S. A., Canham, E. M., Patel, M., McMurtry, I. F., Morris, H. G., and Repine, J. E., 1983b, Acetyl glyceryl ether phosphoryl choline-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs, J. Clin. Invest., 71: 351.PubMedCrossRefGoogle Scholar
  10. Lai, F. M., Shepherd, C. A., Cervoni, P., and Wissner, A., 1983, Hypotensive and vasodilatory activity of (+)l-O-octadecyl-2-acetyl glyceryl-3-phosphorylcholine in the normotensive rat, Life Sci., 32: 1159.PubMedCrossRefGoogle Scholar
  11. Ohar, J. A., Pyle, J. A., Waller, K. S., Hyers, T. M., Webster, R. O., and Lagunoff, D., 1990, A rabbit model of pulmonary hypertension induced by the synthetic platelet-activating factor acetylglyceryl ether phosphorylcholine, Am. Rev. Resp. Dis., 141: 104.PubMedGoogle Scholar
  12. Page, C. P., Archer, C. B., Paul, W., and Morley, J., 1984, Paf-acether: a mediator of inflammation and asthma, Trends Pharmacol. Sci., 5: 239.CrossRefGoogle Scholar
  13. Tamura, N., Agrawal, D. K., Suliaman, F. A., and Townley, R. G., 1987, Effects of platelet activating factor on the Chemotaxis of normodense eosinophils from normal subjects, Biochem. Biophys. Res. Commun., 142: 638.PubMedCrossRefGoogle Scholar
  14. Terashita, Z., Imura, Y., Nishikowa, K., and Sumida, S., 1985, Beneficial effects of (Rs)-2-methoxy-3-(Octadecylcarbamoyloxy)propyl 2-(3-thiazolio) ethyl phosphate, a specific PAF antagonist, in endotoxic and anaphylactic shock, Adv. Prostaglan. Throm. Leuk. Res., 15: 715.Google Scholar
  15. Terashita, Z., Imura, Y., Takatani, M., Tsushima, S., and Nishikowa, K., 1987, CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo, J. Pharmacol. Exp. Ther., 242: 263.PubMedGoogle Scholar
  16. Vercellotti, G. M., Yin, H. Q., Gustafson, K. S., and Jacob H. S., 1988, Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage, Blood, 71: 1100.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Najia Jin
    • 1
  • C. Subah Packer
    • 1
  • Rodney A. Rhoades
    • 1
  1. 1.Department of Physiology and BiophysicsIndiana University School of MedicineIndianapolisUSA

Personalised recommendations